DOVA PHARMACEUTICALS INC. overview

Consideration of up to $29.00 per share includes $27.50 per share in upfront cash and an additional $1.50 per share upon regulatory approval of DOPTELET ® for chemotherapy-induced thrombocytopenia (CIT) as a Contingent Value Right (CVR) for a total potential consideration of up to $915 million on a fully diluted basis Acquisition of Dova expected to enhance Sobi’s position as a leader in hematology and orphan diseases and maximize the availability of DOPTELET to patients globally Transaction...

DURHAM, N.C., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 4:10 p.m. ET in New York, NY. A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, www.dova.com . Please log on through Dova's website approximately 10 minutes before the scheduled...

DURHAM, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President & Chief Executive Officer, will present company overviews at two upcoming investor conferences: H.C. Wainwright 21 st Annual Global Investment Conference on Monday, September 9, 2019 at 12:30 p.m. ET in New York, NY. Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 2:30 p.m. ET in New York, NY. A live audio webcast of each...

DURHAM, N.C., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 2:30 p.m. ET in New York, NY. A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, www.dova.com . Please log on through Dova's website approximately 10 minutes before the scheduled...

DOPTELET ® (avatrombopag) approved by U.S. Food and Drug Administration (FDA) for treatment of chronic immune thrombocytopenia (ITP); commercial launch occurred mid-July DOPTELET approved by European Commission (EC) for treatment of severe thrombocytopenia in patients with chronic liver disease (CLD) Second quarter 2019 net sales from DOPTELET of $3.5 million; channel inventory reduced by approximately $450,000 in Q2; prescription referrals increased approximately 7% compared to Q1 Conference...

DURHAM, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Tuesday, August 6, 2019 at 9:00 a.m. ET to discuss second quarter 2019 financial results and recent operational highlights. A question-and-answer session will follow Dova's remarks. To participate on the live call, please dial 866-550-8145 (domestic) or +1-430-775-1344 (international) and provide the conference ID 7784728 five to 10 minutes before the start of the call. A live...

DURHAM, N.C., July 19, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet need, today announced the commercial availability of DOPTELET (avatrombopag) for treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. In June 2019, the U.S. Food and Drug...